Evaluating AHA PREVENT Equations and Lipoprotein(a) in Cardiovascular Risk Stratification: Integrative Insights from MESA and UK Biobank Cohorts

MedXY Editorial Team•Dec 3, 2025•Cardiology

The novel AHA PREVENT equations adequately predict 10-year ASCVD risk across diverse populations, including those with elevated lipoprotein(a) [Lp(a)].
Elevated Lp(a) (≥125 nmol/L) independently associates with increased risk of coronary heart disease (CHD), ASCVD, heart failure (HF), and total cardiovascular disease, particularly in low- and borderline-risk individuals.
Incorporation of Lp(a) into existing PREVENT equations modestly improves risk discrimination and reclassification, with the greatest benefit observed among borderline- and low-risk groups.
Genetic and biomarker analyses affirm Lp(a) as a distinct and clinically relevant risk factor complementary to traditional lipids and calcium scoring in cardiovascular risk assessment.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The novel AHA PREVENT equations adequately predict 10-year ASCVD risk across diverse populations, including those with elevated lipoprotein(a) [Lp(a)].
Elevated Lp(a) (≥125 nmol/L) independently associates with increased risk of coronary heart disease (CHD), ASCVD, heart failure (HF), and total cardiovascular disease, particularly in low- and borderline-risk individuals.
Incorporation of Lp(a) into existing PREVENT equations modestly improves risk discrimination and reclassification, with the greatest benefit observed among borderline- and low-risk groups.
Genetic and biomarker analyses affirm Lp(a) as a distinct and clinically relevant risk factor complementary to traditional lipids and calcium scoring in cardiovascular risk assessment.